Danish Commercial Services Stock News

Recent coverage around Demant (CPSE:DEMANT) has centered on its push into AI-powered, lifestyle-focused hearing devices and a broad footprint across hearing aids, diagnostics, and audio communications, which appears to be supporting current investor interest. See our latest analysis for Demant. At a share price of DKK 223.8, Demant has seen short term momentum pick up, with a 1 month share price return of 3.4% and a year to date share price gain of 4.9%. However, the 1 year total shareholder...

If you are wondering whether Ørsted’s current share price reflects its true worth, this breakdown will help you see how the market’s view lines up with the underlying numbers. The stock last closed at DKK132.45, with returns of 8.3% over the past week, a 3.9% decline over the last 30 days, 3.5% year to date, and a 27.9% decline over the past year, alongside larger drawdowns over 3 and 5 years. These moves have played out as investors continue to reassess listed renewables companies and their...

In late 2025, Vestas announced a wave of new wind turbine orders totaling several gigawatts across Europe, North America, Asia, and Australia, including its first offshore contract in South Korea and multiple long-term service agreements extending up to 30 years. This broad mix of onshore and offshore projects, spread across developed and emerging wind markets, highlights how Vestas is deepening its global footprint while locking in recurring service revenue over the long term. We’ll now...

In February 2025, Danske Bank A/S launched a share buy-back programme of DKK 5.00 billion, authorising repurchases of up to 45,000,000 shares through to 30 January 2026 under European market regulations. In the first week alone, Danske Bank bought back 204,715 shares, an early signal that management is actively using its capital return authorisation. We’ll now examine how this sizeable buy-back programme, and its potential impact on share count, may influence Danske Bank’s investment...

In late December 2025, Novo Nordisk secured FDA approval for and has now launched in the U.S. the Wegovy pill, the first once-daily oral GLP-1 therapy for chronic weight management and cardiovascular risk reduction, supported by Phase 3 data showing substantially greater weight loss than placebo when combined with diet and exercise. The pill’s broad rollout through major pharmacies, telehealth partners such as Ro, LifeMD, Weight Watchers, and platforms like GoodRx and NovoCare meaningfully...

When you see that almost half of the companies in the Entertainment industry in Denmark have price-to-sales ratios (or...

When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 16x, you may consider...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

ISS (CPSE:ISS) has launched a new share buyback programme of up to DKK 3,000 million over 12 months, drawing attention to how the facility services group is handling excess cash and its share capital structure. See our latest analysis for ISS. At a share price of DKK 220.6, ISS has logged an 11.30% 90 day share price return, while its 1 year total shareholder return of 68.80% points to strong momentum that this buyback announcement may be reinforcing rather than reversing. If this kind of...

Genmab A/S recently reaffirmed its 2025 earnings guidance and decided to discontinue further clinical development of acasunlimab after evaluating its portfolio and the evolving competitive landscape. By reallocating resources toward late-stage assets such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina-S), Genmab is sharpening its late-stage antibody pipeline focus. We will now examine how concentrating capital on EPKINLY, petosemtamab and Rina-S could reshape Genmab’s...

In early January 2026, Ørsted and its partner Skyborn Renewables filed a legal complaint in the US challenging the Trump administration’s suspension of the lease for their Revolution Wind offshore project, a roughly US$5.00 billion development that is about 87% complete after a nine-year permitting process. The dispute places one of the most advanced US offshore wind projects, and its planned 2026 power deliveries and thousands of associated jobs, at the center of a high‑stakes test of...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Novo Nordisk (CPSE:NOVO B) has been quietly grinding higher, with the stock up around 7% over the past month, even after a weaker stretch in the past 3 months and year. See our latest analysis for Novo Nordisk. That recent 6.7% one month share price return looks more like a short term reset than a full trend change, given the 1 year total shareholder return of minus 45.1% and 5 year total shareholder return still up 67.2%. This suggests long term believers have been rewarded even as momentum...

Outlook for Vestas Wind Systems Shares After Recent Gains Vestas Wind Systems (CPSE:VWS) has quietly staged a strong comeback, with the stock up about 12% over the past month and roughly 40% in the past 3 months, drawing fresh investor attention. See our latest analysis for Vestas Wind Systems. That recent rebound comes after a tougher few years, with a 1 year total shareholder return of about 72% contrasting sharply with weaker 3 and 5 year total shareholder returns. This suggests momentum...

With a price-to-sales (or "P/S") ratio of 3.5x Zealand Pharma A/S ( CPH:ZEAL ) may be sending very bullish signals at...

The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more...

With a price-to-earnings (or "P/E") ratio of 37.7x Ambu A/S ( CPH:AMBU B ) may be sending very bearish signals at the...

RIAS A/S ( CPH:RIAS B ) is reducing its dividend from last year's comparable payment to DKK26.00 on the 26th of...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Pandora fair value estimate is kr.1,082 Current share price of...

Key Insights Given the large stake in the stock by institutions, Demant's stock price might be vulnerable to their...

Even if it's not a huge purchase, we think it was good to see that David Hojelsen, the Chief Technology Officer of...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...